{
  "id": 4638397,
  "title": "H.C. Wainwright raises Brainsway stock price target on new data",
  "url": "https://urgent.news/2026/08/31/h-c-wainwright-raises-brainsway-stock-price-target-on-new-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T11:42:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-brainsway-stock-price-target-on-new-data-93CH-4882612"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has increased its price target for Brainsway stock to $19.00, up from $17.00, while keeping a Buy rating. The current stock price is $14.30, meaning investors could see a potential gain of approximately 33% if the target is met. Brainsway shares have climbed 84% over the last year, significantly outperforming the broader market.\n\nThe upgrade is based on new peer-reviewed data showing substantial reductions in suicidal ideation among patients suffering from major depressive disorder who received Deep Transcranial Magnetic Stimulation (TMS). This research, titled \"Effects of H-coil TMS on suicidality in major depression: A secondary analysis of data from a multi-site randomized trial comparing accelerated to once-a-day stimulation,\" was published in the Journal of Affective Disorders.\n\nH.C. Wainwright has also adjusted its revenue multiple for Brainsway to 5.6x from 5.1x, taking into account revised forecasts and a moderate expansion of the comparable universe-derived revenue multiple. The company reported a 32% year-over-year revenue growth in the most recent quarter, ending in Q2 2026. However, according to InvestingPro analysis, Brainsway may be overvalued relative to its Fair Value estimate.\n\nFor investors looking for more detailed information, InvestingPro provides 12 ProTips for Brainsway stock, along with comprehensive Pro Research Reports on over 1,400 US equities. The firm has maintained its Buy rating on Brainsway with the higher price target and reiterated this stance in the latest update.\n\nBrainsWay Ltd. recently reported its second-quarter 2026 revenue at $17.1 million, surpassing analysts' expectations of $16.31 million. Adjusted earnings per share also met forecasts at $0.07. The company raised its full-year revenue guidance to a range of $68 million to $70 million, up from the previous forecast of $66 million to $68 million. This growth is attributed to strong demand for BrainsWay's Deep TMS systems and its SWIFT accelerated treatment protocol.\n\nThe company highlighted the success of its treatment platform, noting a 35% increase in revenue from the previous year, driven by higher system sales and increased adoption of SWIFT. Operating income improved significantly, more than quadrupling compared to the same period last year. Additionally, BrainsWay revealed that the SWIFT reimbursement coverage now extends to approximately 57 million individuals covered by insurance in the U.S., reflecting the company's strategic focus on a wider interventional psychiatry platform.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Gain Therapeutics stock rating at buy",
        "url": "https://urgent.news/2026/08/31/h-c-wainwright-reiterates-gain-therapeutics-stock-rating-at-buy",
        "published": "2026-08-31T11:42:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}